Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

335.28
+3.671.11%
Post-market: 335.280.00000.00%19:12 EST
Volume:648.73K
Turnover:217.23M
Market Cap:9.34B
PE:-25.94
High:349.32
Open:332.52
Low:314.39
Close:331.61
52wk High:349.32
52wk Low:26.70
Shares:27.85M
Float Shares:25.78M
Volume Ratio:1.57
T/O Rate:2.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.9227
EPS(LYR):-10.2095
ROE:-75.20%
ROA:-45.09%
PB:27.18
PE(LYR):-32.84

Loading ...

Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results

Benzinga
·
Yesterday

Stock Track | Praxis Precision Medicines Soars 5.12% Intraday on Multiple Analyst Price Target Increases

Stock Track
·
Feb 20

Praxis Precision price target raised to $700 from $500 at Truist

TIPRANKS
·
Feb 20

Truist Boosts Price Target on Praxis Precision Medicines to $700 From $500, Keeps Buy Rating

MT Newswires Live
·
Feb 20

Stock Track | Praxis Precision Medicines Plummets 5.19% Intraday Despite Analyst Price Target Hikes as Wedbush Maintains Underperform Rating

Stock Track
·
Feb 20

JonesTrading Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Feb 20

Praxis Precision Med Is Maintained at Underperform by Wedbush

Dow Jones
·
Feb 20

Praxis Precision price target raised to $305 from $282 at Wells Fargo

TIPRANKS
·
Feb 20

U.S. RESEARCH ROUNDUP-Dropbox, Etsy, Zscaler

Reuters
·
Feb 20

Praxis Precision Medicines: NDA Progress, Robust Pipeline, and Strong Cash Runway Support Buy Rating

TIPRANKS
·
Feb 20

Stock Track | Praxis Precision Medicines Plummets 5.92% Intraday After Q4 Earnings Miss and Widening Losses

Stock Track
·
Feb 19

Praxis Precision Medicines Publishes Corporate Presentation on CNS Pipeline and Commercial Launch Plans

Reuters
·
Feb 19

Earnings Flash (PRAX) Praxis Precision Medicines Posts Q4 Loss $3.50 a Share, vs. FactSet Est of $2.88 Loss

MT Newswires Live
·
Feb 19

Praxis Precision posts bigger Q4 loss as R&D costs grow

Reuters
·
Feb 19

Praxis Precision Medicine Q4 EPS $(3.50) Misses $(3.08) Estimate

Benzinga
·
Feb 19

Praxis reports FY 2025 R&D expenses up 1.75x to USD 267.1 million

Reuters
·
Feb 19

BRIEF-Praxis Precision Q4 EPS USD -3.5

Reuters
·
Feb 19

Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Dow Jones
·
Feb 19

Earning Preview: Praxis Precision Medicines, Inc. Q4 revenue is expected to decrease by 88.06%, and institutional views are bullish

Earnings Agent
·
Feb 12

Praxis Precision Medicines Updates Non-Employee Director Compensation Policy

Reuters
·
Feb 11